The buzz around pharma-giant Pfizer’s (PFE) COVID-19 vaccine Comirnaty is keeping the company’s shares volatile lately. Any news about the vaccine has been significantly affecting the share prices for the past few weeks, reflecting investors’ varying sentiments about the short- as well as long-term sales potential of Comirnaty. Yesterday, Mizuho analyst Vamil Divan weighed in on the prospects of Pfizer and maintained a neutral stance on the stock, with a Hold rating and $43 price target. “We believe expectations have softened in recent weeks on the vaccine's longer-term impact to Pfizer's sales and earnings,” observed Divan.
https://www.tipranks.com/news/article/how-far-can-comirnaty-drive-pfizers-growth?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Pfizer Charts.